论文部分内容阅读
目的:探讨外周血中基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)、金属蛋白酶组织抑制剂-2(TIMP-2)和金属蛋白酶组织抑制剂-1(TIMP-1)与甲状腺癌的相关性。方法:采用酶联免疫吸附法(ELISA)和RT-PCR法检测30例甲状腺癌患者、27例良性甲状腺肿瘤患者和25例健康志愿者外周血中MMP-2、MMP-9、TIMP-2和TIMP-1的表达水平,分析两者与甲状腺癌之间的关系。结果:甲状腺癌、良性甲状腺病变和健康对照组血清中MMP-2的表达分别为(118.88±7.59)、(51.13±6.89)和(47.55±8.61)ng/mL,TIMP-2分别为(70.78±8.58)、(36.05±7.34)和(32.56±7.27)ng/mL,MMP-9分别为(110.18±15.49)、(56.39±10.90)和(49.28±11.64)ng/mL,TIMP-1分别为(63.62±9.95)、(38.53±8.31)和(34.01±8.22)ng/mL。甲状腺癌患者外周血中的表达均明显高于良性甲状腺肿瘤患者和健康志愿者P=0.000;良性甲状腺肿瘤患者和健康志愿者之间差异无统计学意义,P>0.05。结论:外周血中MMP-2、MMP-9、TIMP-2和TIMP-1的表达水平有助于甲状腺肿瘤良恶性的鉴别,是重要的术前评估手段。
Objective: To investigate the expression of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-2 (TIMP-2) and inhibitor of metalloproteinase-1 -1) and thyroid cancer. Methods: The expressions of MMP-2, MMP-9, TIMP-2 and TIMP-2 in peripheral blood of 30 patients with thyroid cancer, 27 patients with benign thyroid neoplasm and 25 healthy volunteers were detected by enzyme linked immunosorbent assay (ELISA) and RT- TIMP-1 expression levels, and analyze the relationship between the two and thyroid cancer. Results: The serum levels of MMP-2 in thyroid cancer, benign thyroid lesion and healthy control group were (118.88 ± 7.59), (51.13 ± 6.89) and (47.55 ± 8.61) ng / mL respectively, and TIMP- (110.18 ± 15.49), (56.39 ± 10.90) and (49.28 ± 11.64) ng / mL respectively, and TIMP-1 was (8.58), (36.05 ± 7.34) and (32.56 ± 7.27) ng / 63.62 ± 9.95), (38.53 ± 8.31) and (34.01 ± 8.22) ng / mL, respectively. The expression of peripheral blood in patients with thyroid cancer were significantly higher than those in benign thyroid tumors and healthy volunteers (P = 0.000). There was no significant difference between healthy thyroid cancer patients and healthy volunteers (P> 0.05). Conclusion: The expression of MMP-2, MMP-9, TIMP-2 and TIMP-1 in peripheral blood contributes to the differentiation of benign and malignant thyroid neoplasms. It is an important preoperative evaluation method.